Table 1 Overview of the characteristics of the included studies.
Randomized controlled trials (n = 26 including 20 trials) | Observational studies (n = 47) | |
|---|---|---|
N (%) | N (%) | |
Ethnic group | ||
Europe | 7 (26.9) | 29 (61.7) |
North America | 19 (73.1) | 12 (25.5) |
Rest of world | – | 6 (12.8) |
Publication year | ||
≤ 2006 | 18 (69.2) | 18 (38.3) |
> 2006 | 8 (30.8) | 29 (61.7) |
Age at baseline, years (median, range) | 63.6 (49.7–75.0) | 60.6 (48.8–77.0) |
Timing of initiation of MHT*, † | ||
Reported | 22 (84.6) | 36 (76.6) |
Unreported | 4 (15.4) | 11 (23.4) |
Underlying diseases | ||
With | 17 (65.4) | 6 (12.8) |
Without | 9 (34.6) | 41 (87.2) |
Regimen type* | ||
Reported | 19 (73.1) | 29 (617) |
Unreported | 7 (26.9) | 18 (38.3) |
Route of administration* | ||
Reported | 25 (96.2) | 21 (44.7) |
Unreported | 1 (3.8) | 26 (55.3) |
Duration of MHT* | ||
Reported | 26 (100.0) | 12 (25.5) |
Unreported | – | 35 (74.5) |
Outcomes* | ||
All-cause death | 16 (61.5) | 15 (31.9) |
Cardiovascular death | 10 (38.5) | 6 (12.8) |
Stroke | 12 () | 14 (29.8) |
VTE | 15 (57.7) | 13 (27.7) |
PE | 7 (26.9) | 4 (8.5) |
MI | 16 (61.5) | 10 (21.3) |
CHD | 4 (15.4) | 7 (14.9) |
Angina | 8 (30.8) | 1 (2.1) |
Revascularization | 7 () | 0 (0.0) |
Follow-up, years (median, range) | 3.4 (0.7–18) | 6.8 (1–21.5) |
Study type* | ||
Cohort study | – | 30 (63.8) |
Case–control study | – | 13 (27.7) |
Nested case–control study | – | 5 (10.6) |
